Zurich-Schlieren, November 4, 2014. Molecular Partners AG has successfully re-launched its Initial Public Offering (IPO). Due to strong interest and demand from both international and Swiss institutional and private investors, Molecular Partners accelerated the timetable and closed the bookbuilding process yesterday, Monday, 5pm CET. Molecular Partners AG has successfully [...]
Symetis Joins Industry Leaders Edwards Lifesciences and Medtronic as Only Companies to Offer Both Transapical and Transfemoral Options for Transcatheter Aortic Heart Valve Delivery LAUSANNE, SWITZERLAND–(Marketwired – Sept. 12, 2014) – Symetis SA, the leading European developer of transcatheter aortic valve implantation (TAVI) systems, announced today the launch of [...]
By Chris Reidy | GLOBE STAFF JUNE 19, 2014 – Bind Therapeutics Inc., a Cambridge-based nanomedicine company that is developing programmable drugs to certain types of cancer, said Thursday it has entered into a research agreement with Swiss drug giant Roche to discover novel treatment of diseases in therapeutic [...]
Partnership will combine novel biologics (DARPins) with Roche drug-conjugate technology Basel, Switzerland / Zurich-Schlieren, Switzerland, 04 December 2013. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Molecular Partners AG today announced that they have entered into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics [...]
Blackhawk Network Acquires Germany-Based Prepaid Leader Retailo as Part of Ongoing International Expansion Strategy Deal brings Blackhawk’s retail network to over 40,000 retail locations in world’s 4th largest economy LONDON – Dec. 2, 2013 – Blackhawk Network announced that it has completed the acquisition of Germany-based Retailo AG, [...]
ECUBLENS, SWITZERLAND – Oct. 28, 2013 – Symetis Inc., a privately-owned Swiss company focused on transcatheter aortic valve implantation (TAVI) systems announced today that it has achieved a symbolic milestone: the implantation of the 1000th ACURATE TA™ transaortic valve. The first ACURATE TA™ valve was implanted in November 2009 [...]
Former Worldwide VP for Regulatory Affairs at Johnson & Johnson Brings Vast Experience in Medical Device Submissions, Approvals and GMP Compliance. MONTREUX, Switzerland, April 13, 2010 – CeQur SA, a company focused on the development and commercialization of insulin delivery systems to improve the management of type 2 diabetes, [...]
CAMBRIDGE, Mass. (EON: Enhanced Online News) BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, announced today the pricing of its initial public offering of 4,700,000 shares of its common stock at a public offering price of $15.00 per share, before underwriting discounts [...]